Participants:18–64 years · 65+ years
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Contact Research Centre

Bladder cancer

Not recruiting

Registered drugNo placebo

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Psoriasis

Not recruiting

Registered drug

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Brodalumab

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Registered drugNo placebo

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Breast cancer+3

Not recruiting

Registered drugNo placebo

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Tiragolumab, Atezolizumab, and Pembrolizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab

Contact Research Centre

Find therapies in clinical trials near you – page 41

601 trials match your criteria

Asthma

Study on the Effects of Povorcitinib for Adults with Moderate to Severe Asthma Not Well Controlled

Bronchiectasis

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Chronic cutaneous lupus erythematosus

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Adenocarcinoma gastric+1

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

Bladder cancer

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Psoriasis

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Hepatocellular carcinoma

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Breast cancer+3

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Non-small cell lung cancer

Study of Tiragolumab, Atezolizumab, and Pembrolizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Chronic lymphocytic leukaemia+2

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Dermatitis atopic

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.